Barclays’s Iterum Therapeutics ITRM Stock Holding History

Barclays’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$539	Buy	+10,795	New	+$539	﹤0.01%	4995
2025 Q1	–	Sell	-500	Closed	-$885	–	5396
2024 Q4	$885	Buy	+500	New	+$784	﹤0.01%	5144
2021 Q2	–	Sell	-3,333	Closed	-$71K	–	4967
2021 Q1	$71K	Buy	+3,333	New	+$79.3K	﹤0.01%	4119
2020 Q4	–	Sell	-2,667	Closed	-$42K	–	5041
2020 Q3	$42K	Buy	+2,667	New	+$35.6K	﹤0.01%	4684

Other funds holding ITRM

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

Barclays's ITRM Position: Q2 2026 in Review

Barclays opened a new position in Iterum Therapeutics (ITRM) in Q2 2026: 10,795 shares worth $539. The stake represents ﹤0.01% of the portfolio and ranks #4995 among its holdings. This is a return to the name: Barclays previously reported a position in ITRM as recently as Q4 2024.

Barclays first reported a position in ITRM in Q3 2020 and has held it in 4 quarters since. The position peaked at $71K in Q1 2021. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

Barclays held 10,795 shares of Iterum Therapeutics worth $539 as of Q2 2026.
Iterum Therapeutics was a new Barclays position in Q2 2026.
Iterum Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4995 holding.
Barclays first reported a position in Iterum Therapeutics in Q3 2020 and has held it in 4 quarters since.
Barclays's Iterum Therapeutics position peaked at $71K in Q1 2021.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.